BACKGROUND: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. METHODS AND RESULTS: We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease-causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G-). Patients were followed up for a median of 7.8 years (interquartile range, 3.5-13.4 years); HCM end points were examined by cumulative event incidence. Over follow-up, 135 (9%) patients died, 33 from a variety of HCM-related causes. After adjusting for age, all-cause and HCM-related mortality did not differ between G- versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46-1.31]; P=0.37; HR, 0.93 [95% CI, 0.38-2.30]; P=0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G- versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63-2.26]; P=0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88-2.21]; P=0.16). In multivariable analysis, age was the only independent predictor of all-cause and HCM-related mortality, heart failure progression, and sudden death events. CONCLUSIONS: In this large consecutive cohort of patients with HCM, genotype (G+ or G-) was not a predictor of clinical course, including all-cause and HCM-related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.

Department of Biology and Medical Genetics 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Cardiology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Division of Cardiology Peter Munk Cardiac Centre Toronto General Hospital University Health Network Ontario Canada

Hypertrophic Cardiomyopathy Center Lahey Hospital and Medical Center Burlington MA USA

Institute for Clinical Research and Health Policy Studies Tufts Medical Center Boston MA USA

Molecular Cardiology Research Institute Tufts Medical Center Boston MA USA

Zobrazit více v PubMed

Watkins H, Rosenzweig A, Hwang D‐S, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108–1114. doi: 10.1056/NEJM199204233261703 PubMed DOI

Lopes LR, Rahman MS, Elliott PM. A systematic review and meta‐analysis of genotype–phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99:1800–1811. doi: 10.1136/heartjnl-2013-303939 PubMed DOI

Ingles JC, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;4:e59–e59. doi: 10.1136/jmg.2005.033886 PubMed DOI PMC

Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy. Circulation. 2018;138:1387–1398. doi: 10.1161/CIRCULATIONAHA.117.033200 PubMed DOI PMC

Bonaventura J, Polakova E, Vejtasova V, Veselka J. Genetic testing in patients with hypertrophic cardiomyopathy. Int J Mol Sci. 2021;22:10401. doi: 10.3390/ijms221910401 PubMed DOI PMC

Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60:705–715. doi: 10.1016/j.jacc.2012.02.068 PubMed DOI

Sedaghat‐Hamedani F, Kayvanpour E, Tugrul OF, Lai A, Amr A, Haas J, Proctor T, Ehlermann P, Jensen K, Katus HA, et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta‐analysis on 7675 individuals. Clin Res Cardiol. 2018;107:30–41. doi: 10.1007/s00392-017-1155-5 PubMed DOI

Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circulation. 2020;142:558–631. PubMed

Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales‐Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503–3626. doi: 10.1093/eurheartj/ehad194 PubMed DOI

Maron BJ, Rowin EJ, Arkun K, Rastegar H, Larson AM, Maron MS, Chin MT. Adult monozygotic twins with hypertrophic cardiomyopathy and identical disease expression and clinical course. Am J Cardiol. 2020;127:135–138. doi: 10.1016/j.amjcard.2020.04.020 PubMed DOI

Bonaventura J, Norambuena P, Tomasov P, Jindrova D, Sediva H, Macek M Jr, Veselka J. The utility of the Mayo Score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy. Arch Med Sci. 2019;15:641–649. doi: 10.5114/aoms.2018.78767 PubMed DOI PMC

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier‐Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–423. doi: 10.1038/gim.2015.30 PubMed DOI PMC

Whiffin N, Walsh R, Govind R, Edwards M, Ahmad M, Zhang X, Tayal U, Buchan R, Midwinter W, Wilk AE, et al. CardioClassifier: disease‐ and gene‐specific computational decision support for clinical genome interpretation. Genet Med. 2018;20:1246–1254. doi: 10.1038/gim.2017.258 PubMed DOI PMC

Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ, Mazzarotto F, Blair E, Seller A, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19:192–203. doi: 10.1038/gim.2016.90 PubMed DOI PMC

Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79:390–414. doi: 10.1016/j.jacc.2021.11.021 PubMed DOI

Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high‐risk patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2019;4:644–657. doi: 10.1001/jamacardio.2019.1391 PubMed DOI PMC

Zhang X, Zhang MJ. SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Prog Biomed. 2011;101:87–93. doi: 10.1016/j.cmpb.2010.07.005 PubMed DOI PMC

Bonaventura J, Krebsová A, Zoubková V, Votýpka P, Peldová P, Petřková J, Kautzner J, Macek M Jr, Veselka J. Complex approach towards patients with hypertrophic cardiomyopathy and indications to genetic testing. Cor Vasa. 2020;62:272–278. doi: 10.33678/cor.2020.023 DOI

Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2019;73:1978–1986. doi: 10.1016/j.jacc.2019.01.061 PubMed DOI PMC

Li Q, Gruner C, Chan RH, Care M, Siminovitch K, Williams L, Woo A, Rakowski H. Genotype‐positive status in patients with hypertrophic cardiomyopathy is sssociated with higher rates of heart failure events. Circ Cardiovasc Genet. 2014;7:416–422. doi: 10.1161/CIRCGENETICS.113.000331 PubMed DOI

Lorenzini M, Norrish G, Field E, Cicerchia M, Akhtar MM, Syrris P, Lopes LR, Kaski JP, Elliott PM. Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers. J Am Coll Cardiol. 2020;76:550–559. doi: 10.1016/j.jacc.2020.06.011 PubMed DOI PMC

Lopes LR, Syrris P, Guttmann OP, O'Mahony C, Tang HC, Dalageorgou C, Jenkins S, Hubank M, Monserrat L, McKenna WJ, et al. Novel genotype–phenotype associations demonstrated by high‐throughput sequencing in patients with hypertrophic cardiomyopathy. Heart. 2015;101:294–301. doi: 10.1136/heartjnl-2014-306387 PubMed DOI PMC

Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65:1915–1928. doi: 10.1016/j.jacc.2015.02.061 PubMed DOI

van Velzen HG, Vriesendorp PA, Oldenburg RA, van Slegtenhorst MA, van der Velden J, Schinkel AFL, Michels M. Value of genetic testing for the prediction of long‐term outcome in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016;118:881–887. doi: 10.1016/j.amjcard.2016.06.038 PubMed DOI

Bonaventura J, Norambuena P, Votýpka P, Hnátová H, Adlová R, Macek M Jr, Veselka J. Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long‐term outcome irrespective of their genetic background. Cardiovasc Diagn Ther. 2020;10:193–200. doi: 10.21037/cdt.2020.01.12 PubMed DOI PMC

Olivotto I, Oreziak A, Barriales‐Villa R, Abraham TP, Masri A, Garcia‐Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER‐HCM): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2020;396:759–769. doi: 10.1016/S0140-6736(20)31792-X PubMed DOI

Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower‐Rader A, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR‐HCM randomized clinical trial. JAMA Cardiol. 2023;8:968–977. doi: 10.1001/jamacardio.2023.3342 PubMed DOI PMC

Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first‐in‐class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J. 2023;00:1–12. doi: 10.1093/eurheartj/ehad637 PubMed DOI PMC

Murphy SL, Anderson JH, Kapplinger JD, Kruisselbrink TM, Gersh BJ, Ommen SR, Ackerman MJ, Bos JM. Evaluation of the Mayo Clinic phenotype‐based genotype predictor score in patients with clinically diagnosed hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2016;9:153–161. doi: 10.1007/s12265-016-9681-5 PubMed DOI PMC

Neubauer S, Kolm P, Ho CY, Desai MY, Dolman SF, Appelbaum E, Desvigne‐Nickens P, DiMarco JP, Friedrich MG, Geller N, et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol. 2019;74:2333–2345. doi: 10.1016/j.jacc.2019.08.1057 PubMed DOI PMC

Gruner C, Ivanov J, Care M, Williams L, Moravsky G, Yang H, Laczay B, Siminovitch K, Woo A, Rakowski H. Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2013;6:19–26. doi: 10.1161/CIRCGENETICS.112.963363 PubMed DOI

Mörner S, Richard P, Kazzam E, Hellman U, Hainque B, Schwartz K, Waldenström A. Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden. J Mol Cell Cardiol. 2003;35:841–849. doi: 10.1016/S0022-2828(03)00146-9 PubMed DOI

Garcia‐Castro M, Coto E, Reguero JR, Berrazueta JR, Alvarez V, Alonso B, Sainz R, Martín M, Morís C. Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2009;62:48–56. doi: 10.1016/S0300-8932(09)70020-X PubMed DOI

Laredo R, Monserrat L, Hermida‐Prieto M, Fernández X, Rodríguez I, Cazón L, Alvariño I, Dumont C, Piñón P, Peteiro J, et al. Beta‐myosin heavy‐chain gene mutations in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2006;59:1008–1018. doi: 10.1157/13093977 PubMed DOI

Rodriguez‐Garcia MI, Monserrat L, Ortiz M, Fernández X, Cazón L, Núñez L, Barriales‐Villa R, Maneiro E, Veira E, Castro‐Beiras A, et al. Screening mutations in myosin binding protein C3 gene in a cohort of patients with Hypertrophic Cardiomyopathy. BMC Med Genet. 2010;11:67. doi: 10.1186/1471-2350-11-67 PubMed DOI PMC

Hathaway J, Heliö K, Saarinen I, Tallila J, Seppälä EH, Tuupanen S, Turpeinen H, Kangas‐Kontio T, Schleit J, Tommiska J, et al. Diagnostic yield of genetic testing in a heterogeneous cohort of 1376 HCM patients. BMC Cardiovasc Disord. 2021;21:126. doi: 10.1186/s12872-021-01927-5 PubMed DOI PMC

Lakdawala NK, Olivotto I, Day SM, Han L, Ashley EA, Michels M, Ingles J, Semsarian C, Jacoby D, Jefferies JL, et al. Associations between female sex, sarcomere variants, and clinical outcomes in hypertrophic cardiomyopathy. Circ Genom Precis Med. 2021;14:E003062. doi: 10.1161/CIRCGEN.120.003062 PubMed DOI

Ingles J, Burns C, Bagnall RD, Lam L, Yeates L, Sarina T, Puranik R, Briffa T, Atherton JJ, Driscoll T, et al. Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications. Circ Cardiovasc Genet. 2017;10:e001620. doi: 10.1161/CIRCGENETICS.116.001620 PubMed DOI

Ingles J, Sarina T, Yeates L, Hunt L, Macciocca I, McCormack L, Winship I, McGaughran J, Atherton J, Semsarian C. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15:972–977. doi: 10.1038/gim.2013.44 PubMed DOI

Andersen PS, Havndrup O, Hougs L, Sørensen KM, Jensen M, Larsen LA, Hedley P, Thomsen AR, Moolman‐Smook J, Christiansen M, et al. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum Mutat. 2009;30:363–370. doi: 10.1002/humu.20862 PubMed DOI

Charron P, Elliott PM, Gimeno JR, aforio ALP, Kaski JP, Tavazzi L, Tendera M, Maupain C, Laroche C, Rubis P, et al. The cardiomyopathy registry of the EURObservational research programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018;39:1784–1793. doi: 10.1093/eurheartj/ehx819 PubMed DOI

Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, Dougherty K, Harrison SM, McGlaughon J, Milko LV, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med. 2019;12:e002460. doi: 10.1161/CIRCGEN.119.002460 PubMed DOI PMC

Das KJ, Ingles J, Bagnall RD, Semsarian C. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. Genet Med. 2014;16:286–293. doi: 10.1038/gim.2013.138 PubMed DOI

Furqan A, Arscott P, Girolami F, Cirino AL, Michels M, Day SM, Olivotto I, Ho CY, Ashley E, Green EM, et al. Care in specialized centers and data haring increase agreement in hypertrophic cardiomyopathy genetic test interpretation. Circ Cardiovasc Genet. 2017;10:e001700. doi: 10.1161/CIRCGENETICS.116.001700 PubMed DOI

Maron BA, Wang R‐S, Carnethon MR, Rowin EJ, Loscalzo J, Maron BJ, Maron MS. What causes hypertrophic cardiomyopathy? Am J Cardiol. 2022;179:74–82. doi: 10.1016/j.amjcard.2022.06.017 PubMed DOI PMC

Bonaventura J, Rowin EJ, Maron MS, Maron BJ. Is hypertrophic cardiomyopathy always a familial and inherited disease? J Am Heart Assoc. 2023;12:e028974. doi: 10.1161/JAHA.122.028974 PubMed DOI PMC

Walsh R, Offerhaus JA, Tadros R, Bezzina CR. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. Nat Rev Cardiol. 2021;19:1–17. PubMed

Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, Waring A, Ormondroyd E, Kramer CM, Ho CY, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet. 2021;53:135–142. doi: 10.1038/s41588-020-00764-0 PubMed DOI PMC

Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, Kelu Bisabu K, Walsh R, Hoorntje ET, Te Rijdt WP, et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet. 2021;53:128–134. doi: 10.1038/s41588-020-00762-2 PubMed DOI PMC

Wu G, Liu J, Ruan J, Yu S, Wang L, Zhao S, Wang S, Kang L, Wang J, Song L. Deleterious rare desmosomal variants contribute to hypertrophic cardiomyopathy and are associated with distinctive clinical features. Can J Cardiol. 2022;38:41–48. doi: 10.1016/j.cjca.2021.08.022 PubMed DOI

Watkins H. Time to think differently about sarcomere‐negative hypertrophic cardiomyopathy. Circulation. 2021;143:2415–2417. doi: 10.1161/CIRCULATIONAHA.121.053527 PubMed DOI